Biotech Values

[oc631]

Interesting. So, they are dropping [GS 9190] from these trials, which also includes one of their PIs (GS 9451 or GS 9256), pegylated interferon, and ribavirin.

The P.I.'s appear to be getting a clean bill because single SAE's were experienced in separate studies which is understandable in hindsight. If GS9190 is responsible for the SAE's (which I feel is more than likely) GILD may setback their protease inhibitor development program if SAE's reappear again in oral combo studies.